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Abstract 32 
The development of methods to increase the bioavailability of drugs is of great interest, 33 
especially for those which are poorly soluble or permeable. One of the strategies to 34 
enhance the solubility (which in turn has the potential of increase bioavailability) of 35 
drugs is the use of additives in the formulation process, so that the drug can stay 36 
supersaturated in biological fluids for a period of time long enough to allow absorption. 37 
The use of polymers as pharmaceutical excipients in order to stabilize the 38 
supersaturation of drugs is common practice. In this work, the ability of different 39 
polymers of vinylpyrrolidone (K-12, K-17, K-25, K-29/32, K-90) and a copolymer of 40 
vinylpyrrolidone and vinylacetate (S-630) have been tested for their impact on the 41 
supersaturation of drugs. Sixteen drugs of different chemical nature have been 42 
selected, and analyzed using the Cheqsol method. The results of the drug alone, and 43 
of physical mixtures with the different polymers at several polymer:drug ratios have 44 
been compared in terms of supersaturation extent and duration. It has been observed 45 
that acidic compounds displayed enhanced solubility in different ways: sometimes the 46 
supersaturated state of the drug is maintained for a long time, due to the precipitation 47 
of an amorphous solid, as determined by X-ray diffraction studies; on other occasions 48 
supersaturation increases but only for a short time, compared to the drug alone, and 49 
then the drug precipitates to a crystalline form. Only a few basic drugs displayed 50 
enhanced solubility in the presence of PVP polymers, in contrast to acidic compounds.  51 
 52 
  53 
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1. Introduction 54 
Pharmaceutical compounds obtained with new synthesis procedures have tended 55 
towards higher molecular weights and lipophilicity, which allows drugs to cross 56 
membranes more easily. However, molecular properties that promote permeation often 57 
decrease solubility, and then bioavailability is diminished. In addition, some poorly 58 
water-soluble molecules are also not very lipophilic (Box and Comer, 2008). To 59 
understand the relationship between solubility and permeability, and visualize its 60 
potential impact on drug absorption, the Biopharmaceutics Classification Scheme 61 
(BCS) is used (FDA Guidance, 2015). This scheme classifies all molecules in 4 62 
different classes on the basis of solubility and permeability. Molecules in class I are 63 
considered to be highly soluble and highly permeable, very suitable for pharmaceutical 64 
purposes. Molecules in class II have limited solubility but are permeable, while 65 
molecules in Class III are soluble but poorly permeable. Finally, molecules in Class IV 66 
have low solubility and low permeability (Box and Comer, 2008; Tsume et al., 2014).  67 
In order to achieve desirable drug absorption, active molecules should be soluble to a 68 
given extent in aqueous media to ensure they are dissolved in biological fluids once 69 
inside the human body (Takács-Novák et al., 2013). Therefore, aqueous solubility is, 70 
amongst others, an essential property to assess during early stages of drug 71 
development (Shoghi et al., 2013). Several methods can be used to increase drug 72 
solubility, especially for class II compounds which often exhibit solubility-limited 73 
absorption. Some of them are focused on solubilizing formulations (i.e. enhancing the 74 
solubilizing capacity in the gastrointestinal environment), and other methods are 75 
focused on maintaining the drug in a supersaturated state, so it can be available at 76 
higher concentrations than its equilibrium solubility for a certain period of time (Williams 77 
et al., 2013; Brouwers et al. 2009). However, it must be considered that solubility 78 
increase in biological fluids may only need to be fleeting, so the maintenance of a 79 
temporary state of supersaturation would be enough to make the drug available for 80 
permeation (Warren et al., 2010). In other words, keeping the concentration of the drug 81 
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higher than its equilibrium intrinsic solubility only during the digestion time may be 82 
sufficient to promote absorption.  83 
For pure drugs, kinetic solubility Sk (or concentration when first precipitation occurs) is 84 
generally higher than the intrinsic solubility S0, indicating that the drug solution is 85 
frequently supersaturated just before precipitate is first observed (Box and Comer, 86 
2008; Shoghi et al., 2009). However, a supersaturated drug solution is 87 
thermodynamically unstable and has the tendency to return to the equilibrium state by 88 
precipitation to the crystalline most stable form of the drug. This process can be slowed 89 
down or inhibited using some solubility enhancement strategies ((Williams et al., 2013; 90 
Brouwers et al. 2009; Xu and Dai, 2013; Ilevbare et al., 2013). Among other 91 
approaches, the use of different pharmaceutical excipients like polymers, surfactants or 92 
cyclodextrins as stabilizers of supersaturation is common practice. In these cases, the 93 
stabilizer effect does depend not only on the type of stabilizer, but also on the 94 
excipient:drug ratio, and the initial degree of supersaturation of the drug (Brouwers et 95 
al. 2009; Ilevbare et al., 2013; Khougaz and Clas, 2000; Chauhan et al., 2013).  96 
Poly(vinylpyrrolidone) (PVP) polymers have been extensively studied regarding their 97 
ability to modify drugs’ solubility. Some works are centered on the impact of PVP on 98 
the inhibition of crystallization of drugs (Khougaz and Clas, 2000; Chauhan et al., 2013; 99 
Ozaki et al., 2013); other works are focused on the knowledge of the specific 100 
interactions between drugs and PVP (Khougaz and Clas, 2000; Karavas et al., 2006; 101 
Karavas et al., 2007; Tajber et al., 2005; Nair et al., 2001; Molyneux and Frank, 1961a; 102 
Molyneux and Frank, 1961b) which, according to FTIR experiments, seems to be 103 
related to the ability of PVP units to form hydrogen bonds either through the nitrogen or 104 
the carbonyl group on the pyrrole ring. Most of these studies employ only one particular 105 
type of PVP (i.e. with a particular degree of polymerization, which ranges from 12 to 90 106 
in the above mentioned studies) and a few different drugs. In the present work, a 107 
systematic study taking into account the degree of polymerization of the PVP and the 108 
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PVP:drug ratio is addressed. In particular, the effect of these two parameters on the 109 
degree and extent of supersaturation of different BCS class II drugs is evaluated.  110 
 111 
 112 
2. Materials and methods 113 
2.1. Instruments 114 
All solubility assays were carried out by the CheqSol method (Stuart and Box, 115 
2005) using a PCA200 titrator from Sirius Analytical Instruments Ltd. (Forest Row, UK), 116 
equipped with a Sirius D-PAS spectrometer, a bifurcated fibre-optic dip probe from 117 
Hellma Analytics (Müllheim, Germany) with path length of 1 cm, and a two channels 118 
solvent degasser from SMI-LabHut Ltd. (Churcham, UK). The apparatus was controlled 119 
from a computer running the RefinementPro2 and Cheqsol software. Acidity constant 120 
determinations were performed using either the PCA220 or a GLpKa titrator also from 121 
Sirius Analytical Instruments Ltd. 122 
The X-Ray diffraction (XRD) characterization was performed using a PANalytical X’Pert 123 
PRO MPD / powder diffractometer of 240 mm of radius equipped with a PIXcel 124 
detector from PANalytical B.V. (Almelo, The Netherlands). The apparatus was set in a 125 
configuration of convergent beam with a focalizing mirror and a transmission geometry, 126 
with flat samples sandwiched between low absorbing films. The detector active length 127 
was 3.347º. Work power was 45 kV – 40 mA with a defined beam height of 0.4 mm. 128 
Five repeated scans were performed from 2 to 60 2 º with a step size of 0.026 2º and 129 
a measuring time of 40 seconds per step. 130 
 131 
2.2. Reagents 132 
Dimethyl sulfoxide >99.9% (DMSO), 0.5 M potassium hydroxide tritisol and 0.5 M 133 
hydrochloric acid tritisol were purchased from Merck (Darmstadt, Germany). Potassium 134 
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chloride >99% was from Sigma (St. Louis, MO, USA), and potassium hydrogen 135 
phthalate >99% was from Probus (Strassen, Luxembourg). PVP K-12, K-17, K-25, K-136 
29/32, K-90 and S-630 were from International Specialty Products (Wayne, NJ, USA), 137 
and provided by Ashland (Covington, KY, USA). K-type PVP are homopolymers of 138 
polyvinylpyrrolidone that differ in molecular weight (MW) and glass transition 139 
temperature (Tg); K represents degree of polymerization, thus the higher K the higher 140 
MW and Tg. PVP S-630 is a 60:40 random copolymer of vinylpyrrolidone and 141 
vinylacetate; it has a lower Tg and is less hygroscopic than K-type PVP (Ashland Inc., 142 
2013). Water was purified by a Milli-Q plus system from Millipore (Bedford, MA, USA) 143 
with resistivity of 18.2MΩcm. 144 
A total of 16 test compounds were used. Papaverine hydrochloride (>98%), dibucaine 145 
hydrochloride (>99%), cyproheptadine hydrochloride (99%), bendroflumethiazide (Ref. 146 
Std.), bupivacaine hydrochloride (Ref. Std.), isoxicam (An. Std.), propranolol 147 
hydrochloride (>98.5%), warfarin (>98%), ketoprofen (>98%), and diclofenac sodium 148 
salt (>98.5%) were from Sigma-Aldrich (St. Louis, MO, USA). Benzthiazide (Ref. Std.), 149 
haloperidol (>98%), maprotiline hydrochloride (>99%), olanzapine (>98%), pindolol 150 
(>98%), and tetracaine (>98%) were from Sigma (St. Louis, MO, USA). 151 
 152 
2.3. Procedures 153 
2.3.1. pKa determination 154 
All measurements were performed at least in triplicate, under argon atmosphere, at 25 155 
± 0.1 ºC, using standardized 0.5 M HCl and 0.5 M KOH solutions as titrants. The pH 156 
electrode (Ag/AgCl, Sirius Analytical Instruments Ltd.) was calibrated titrimetrically in 157 
the pH range 1.8-12.2. Temperature was monitored through a temperature probe 158 
during the course of the measurement. 159 
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Spectrophotometric titration was the method of choice to determine acidity constants of 160 
the test compounds. pKa values were determined from pH–dependent multi-wavelength 161 
UV spectra collected by the D-PAS system. In each experiment, 50 L of a drug stock 162 
solution (10 mM in DMSO) were introduced in 10 mL of a 0.15M KCl ionic strength 163 
adjusted (ISA) aqueous solution, and titrated between pH 2 and pH 12. 164 
The pKa of haloperidol and the second pKa of dibucaine, whose ionisable groups 165 
showed not enough UV activity (Allen et al. 1998), were determined through a 166 
conventional potentiometric titration (Albert and Serjeant, 1984) in methanol-water 167 
mixtures. The aqueous pKa values were obtained through Yasuda-Shedlovsky 168 
extrapolation (Avdeef et al, 1993; Takács-Novák et al., 1997; Yasuda, 1959; 169 
Shedlovsky, 1962). 170 
2.3.2. Solubility determination 171 
Solubility measurements were carried out using the CheqSol method, which is 172 
described in detail elsewhere (Stuart and Box, 2005). Briefly, 10 mL of ISA solution are 173 
added to an accurately weighted amount of drug. The pH is immediately adjusted to a 174 
value where the compound exists predominantly in its ionized form, titration starts (by 175 
addition of amounts of KOH or HCl, according to the nature of the compound), and 176 
solubility is reduced by increasing the concentration of the neutral species. When a 177 
certain extent of supersaturation is achieved, precipitation starts. At this point, small 178 
amounts of acidic and basic titrant are alternately added, creating subsequent positive 179 
and negative pH gradients, which in turn make the drug solution go alternately from 180 
subsaturated to supersaturated. The solubility of the neutral species (S0) is determined 181 
from the point at which the pH gradient becomes zero, i.e. where no net dissolution or 182 
precipitation of the compound occurs, through mass and charge balances and the pKa 183 
of the compound. All measurements were performed at least in triplicate. 184 
The weight of sample needed to perform the assay depends on the compound’s 185 
intrinsic solubility and may vary between 5.00-20.00 mg. The temperature was set to 186 
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25±0.5°C and an argon atmosphere was used to avoid the presence of carbon dioxide 187 
in solution and its influence on the titration data. When carrying out the solubility 188 
assays in the presence of PVP, a physical mixture of the drug and the PVP was used. 189 
The percentage of PVP in the assay was calculated as follows: 190 
𝑃𝑉𝑃 % =
𝑃𝑉𝑃 𝑤𝑒𝑖𝑔ℎ𝑡
(𝑑𝑟𝑢𝑔 𝑤𝑒𝑖𝑔ℎ𝑡+𝑃𝑉𝑃 𝑤𝑒𝑖𝑔ℎ𝑡)
· 100            (1) 191 
 192 
2.3.3. Supersaturation determination 193 
Extent and time in which a solution stays supersaturated are the parameters used to 194 
evaluate supersaturation. Determinations performed through the CheqSol method 195 
provide this information since the drug concentration is monitored over time. 196 
Henceforth, dividing the maximum measured concentration of neutral species (Cmax) by 197 
the intrinsic solubility (S0), the supersaturation ratio (Rss) can be calculated.  198 
𝑅𝑆𝑆 =  
𝐶𝑚𝑎𝑥
𝑆0
                 (2) 199 
Also the duration of the supersaturation state (tss) can be measured from the 200 
concentration vs. time data by calculating the time lapse Δt in which supersaturation 201 
occurs (Hsieh et al., 2012). 202 
 203 
2.3.4. X-Ray diffraction characterization 204 
In order to characterize the precipitate obtained while the solution is supersaturated, 205 
the solubility assay was aborted at the desired time point. Then, the solid was filtered 206 
through a 0.45 µm filter paper, and the filters were then left in a vacuum dessicator for 207 
one day. The solid material was carefully collected and prepared for XRD 208 
characterization. 209 
 210 
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3. Results and discussion 211 
3.1. Physicochemical properties of studied compounds  212 
Structures of the tested compounds are shown in Table 1. They are of different 213 
chemical nature, and include 2 diprotic acids (bendroflumethiazide and benzthiazide) 214 
which belong to the same family, 4 monoprotic acids (diclofenac, isoxicam, ketoprofen, 215 
and warfarin), 3 diprotic bases (dibucaine, olanzapine and tetracaine), and 7 216 
monoprotic bases (bupivacaine, cyproheptadine, haloperidol, maprotiline, papaverine, 217 
pindolol, and propranolol). pKa  and S0 of the compounds have been determined and 218 
results are also shown in Table 1. Bupivacaine is the most soluble of the drugs with log 219 
S0 = -2.93±0.05, whereas isoxicam is the least soluble with log S0 = -5.61±0.14. It is 220 
normal behavior that compounds show a certain degree of supersaturation just before 221 
precipitation occurs (Hsieh et al., 2012). For this reason, it is important to know the 222 
extent of the supersaturation of the compound itself, so that the effect of the addition of 223 
PVP can be correctly interpreted. The maximum concentration of neutral species 224 
(Cmax), and supersaturation ratio (Rss) and time (tss) of the drugs are also provided in 225 
Table 1. As an example, Figure 1 shows the concentration profile of 226 
bendroflumethiazide during a typical Cheqsol experiment. In this exemplary experiment 227 
Cmax is around 1500 M, whereas S0 is 80 M, which provides a Rss around 18, i.e. the 228 
concentration of bendroflumethiazide is 18 times higher than its equilibrium solubility 229 
just before precipitation starts. In this example the duration of the supersaturation state, 230 
tss, is about 12 minutes. Values provided in Table 1 are the average of several replicate 231 
measurements. It can be observed that Cmax and tsat often have high standard 232 
deviations. This is not unusual because as supersaturation is a non-equilibrium 233 
process, it can be easily affected by many environmental factors, which lead to high 234 
dispersion in the obtained values even in replicate measurements. According to the 235 
obtained results, papaverine and isoxicam are the compounds that supersaturate most 236 
highly, compared to the intrinsic solubility, reaching concentrations almost sixty-fold 237 
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greater than S0. On the contrary, bupivacaine and tetracaine hardly supersaturate, 238 
since the ratio Cmax/S0 is close to 1. With regards to supersaturation time, the longest 239 
supersaturation times following precipitation are around 15-20 minutes, whereas the 240 
shortest ones are in the range 4-5 minutes.  241 
 242 
3.2. Effect of PVP on the solubility of the drugs 243 
To check the effect of PVP on drugs solubility, Cheqsol experiments were repeated 244 
using physical mixtures of drug-PVP. The effect of all available PVP at different 245 
PVP:drug proportions was tested. Three different trends were observed for the 246 
selected compounds related to their supersaturation, and three model compounds 247 
have been selected to explain each one of the behaviors: bendroflumethiazide (case 248 
A), benzthiazide (case B), and tetracaine (case C). 249 
3.2.1. Case A: long-time stabilization of the supersaturated state 250 
This is the case of bendroflumethiazide, diclofenac, ketoprofen, and warfarin. Figure 2A 251 
shows how the concentration of bendroflumethiazide changes with time when different 252 
proportions of PVP K-12 are present in the mixture. In the absence of PVP, after 253 
reaching Cmax, concentration decreases until the S0 value is reached. However, when 254 
PVP are present, solutions stay supersaturated at nearly the Cmax concentration of the 255 
drug for the whole duration of the experiment. So, in this case PVP do not increase the 256 
maximum concentration of drug in solution, but keep this concentration stable for a 257 
long time, improving the potential bioavailability. As regards the effect of the PVP:drug 258 
ratio, there is a slight decrease of supersaturation concentration when the percentage 259 
of PVP increases. Nevertheless, all solutions keep supersaturated at all ratios 260 
PVP:drug, with degrees ranging from 7.6 (70%) to 15 (10%) for more than 2 hours. It is 261 
worth noting that the reproducibility between replicate measurements is more variable 262 
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at low PVP:drug ratios (Figure 2B). Best reproducibility is obtained in the range 40-70% 263 
PVP. 264 
The effect of the PVP polymerization degree has also been tested. Figure 3 shows the 265 
results of solubility measurements for bendroflumethiazide when different PVP (all of 266 
them in a 50% PVP:drug ratio) are used. Apparently there is no effect of the degree of 267 
polymerization on the supersaturation of the drug, since all K-type PVP provide the 268 
same results. Previous studies based on FTIR measurements had already pointed out 269 
existing interactions between bendroflumethiazide and K-type PVP (Tajber et al., 2005, 270 
Frontini and Mielck, 1997), mainly through hydrogen bonding interactions of the 271 
sulfonamide groups of bendroflumethiazide and the vinylpyrrolidone units. However, 272 
PVP S-630, which contains vinylacetate moieties randomly distributed in addition to the 273 
vinylpyrrolidone ones, hardly modifies solubility behavior of bendroflumethiazide. This 274 
latter polymer was tested at different PVP:drug ratios obtaining similar results (Table 275 
S1 of the supporting material) at all S-630 levels. 276 
Diclofenac, ketoprofen and warfarin behave as bendroflumethiazide in the presence of 277 
PVP. Results for these three other compounds are shown in Figure 4. Diclofenac (Fig. 278 
4A) and ketoprofen (Fig. 4B) interact only with K-type PVP, and solubility of the 279 
compounds is stabilized at 17-fold and 2-fold its intrinsic solubility value, respectively. 280 
Warfarin (Fig. 4C) shows positive interaction not only with K-type PVP, but also with 281 
PVP S-630. All types of PVP make the solubility of warfarin increase approximately 20 282 
times.  283 
3.2.2. Case B: increase of the supersaturation concentration for a limited time 284 
In this other case, the effect of PVP on drug’s solubility is completely different. Now, the 285 
addition of PVP makes Cmax of the drugs increase, but for a limited period of time. 286 
Thus, the drug could be potentially more bioavailable, but because of the higher 287 
concentration in the supersaturated solution. This is the case of benzthiazide, isoxicam, 288 
olanzapine, and pindolol. Focusing on benzthiazide as a model compound, the addition 289 
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of K-type PVP makes Cmax increase from around 100 M to about 1000 M, depending 290 
on the added PVP and its percentage (Table S2 of the supporting material). In the 291 
same way, supersaturation time increases from 4 minutes (benzthiazide alone) to a 292 
range between 15 and 45 minutes, depending on the PVP and percentage added. 293 
There is not a clear trend that relates Rss with the polymerization degree or the 294 
percentage of PVP. However, it seems that higher percentages of PVP enlarge the 295 
supersaturation time of the drug. The addition of PVP S-630 provokes a greater effect 296 
than K-type PVP on benzthiazide solubility (Figure 5A). Rss is increased from 8 to 44 297 
when the percentage of S-630 is 10%, to 109 when it is 50%, and to 720 at 75% of 298 
PVP. In the same way, supersaturation time increases from 4 minutes to around 25, 299 
30, and 40 minutes at 10%, 50%, and 75% S-630 respectively. 300 
Although the general effect on solubility is the same for all mentioned compounds (an 301 
increase in the supersaturation concentration for a given period of time), the results 302 
obtained for each individual compound may change according the type of PVP and its 303 
percentage. For example, pindolol has a similar increase in supersaturation ratio (from 304 
15 to 50-60) and time (from 6 to 20-30 minutes) independently of the percentage and 305 
type of PVP used (Figure 5B). However olanzapine shows a moderate increase in 306 
supersaturation degree depending on the used PVP, and also an important 307 
modification in the supersaturation time; it changes from nearly 6 minutes to 25 308 
minutes with a 65% S-630 addition (Figure 5C). Similar behavior is observed for 309 
isoxicam (Figure 5D), which shows a Rss around two times the level of the compound 310 
alone, and a tss 3 or 4-fold higher. The results obtained as regards Cmax, Rss and tss for 311 
the aforementioned compounds are summarized in Table S2 of the supplementary 312 
information. 313 
3.2.3. Case C: no effect on the solubility of the drugs 314 
In the third case there is no interaction at all between the drug and the different PVP, 315 
so that solubility is not affected by the addition of the polymers. This happens to 316 
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bupivacaine, cyproheptadine, dibucaine, haloperidol, maprotiline, papaverine, 317 
propranolol, and tetracaine. Figure 6 shows the supersaturation profile of tetracaine in 318 
absence and presence of 50% of K-type and S-630 PVP. In all instances the profile is 319 
identical, and practically the same results are obtained at other percentages (Table S3 320 
of the supplementary information). Although small increases in ts are observed in some 321 
instances, they can be attributed to the kinetic factors which can delay or accelerate 322 
the precipitation of a compound.   323 
 324 
3.3. Effect of PVP on the morphology of the precipitates 325 
X-Ray diffraction (XRD) assays were performed for the two model compounds that 326 
presented a clear modification of solubility behavior in presence of PVP, i.e. 327 
bendroflumethiazide and benzthiazide. This analysis was performed with the PVP that 328 
caused stronger modifications to the solubility of the mentioned compounds, so K-12 329 
was chosen for bendroflumethiazide and S-630 for benzthiazide. The aim was to 330 
assess if observed changes in drugs solubility behaviors were due to modifications in 331 
solid forms when precipitation occurred, induced by the presence of PVP. XRD spectra 332 
were performed on the commercial drug samples, pure K-12 and S-630 PVP, the solid 333 
obtained after drug precipitation during Cheqsol determinations in the absence of PVP, 334 
and the solid obtained during Cheqsol determinations in the presence of PVP. Results 335 
can be observed in Figure 7. Pure drugs spectra (a) show high intensity peaks 336 
reporting periodic arrangement of atoms, thus, crystalline solids. After Cheqsol 337 
experiments in absence of PVP (b) all drugs precipitate also in a crystalline form, but 338 
different from the initial one, so both compounds show some kind of polymorphism. 339 
Thus, intrinsic solubility reported for the drugs correspond to the obtained polymorph, 340 
and not to the original crystalline form. The spectra obtained for both pure PVP (K-12 341 
and S-630) are very similar (c), and characterized by the absence of sharp peaks. 342 
Instead, wide bands are observed, which are indicative of amorphous solids. Finally, 343 
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Cheqsol determinations were repeated in the presence of 50% of K-12 (for 344 
bendroflumethiazide) and 50% S-630 (for benzthiazide). Spectra show different results 345 
in this case. Bendroflumethiazide spectra belongs to an amorphous solid (Fig 7A,d). 346 
Only two sharp peaks are present, which belong to the KCl present in the titration 347 
measurements. In this case PVP induces the precipitation of a metastable amorphous 348 
form, with higher solubility than the crystalline one (Hsieh et al., 2012). Instead, the 349 
spectra obtained for benzthiazide (Fig 7B,d) belongs to a crystalline solid, and can be 350 
considered equivalent to the one obtained in absence of PVP. In this case the 351 
presence of PVP may inhibit precipitation, and higher concentrations of drug can be 352 
reached in solution. However, after a relative short time the polymorph of benzthiazide 353 
starts to precipitate in the same form obtained in absence of PVP, so concentration in 354 
solution falls to the S0 value. 355 
According to the observed results it is difficult to predict a clear effect of PVP on a 356 
given drug. However, it must be pointed out that all the acidic compounds of the 357 
present work modify its solubility behavior in presence of PVP; on the other hand, 358 
solubility of basic compounds is hardly affected by PVP, although some bases like 359 
olanzapine and pindolol improved temporarily their supersaturation degree and 360 
duration by the addition of PVP. Molyneux et al. (Molyneux and Frank, 1961a; 361 
Molyneux and Frank, 1961b) already indicated that anionic aromatic compounds 362 
interact with PVP polymers. They demonstrated that the binding constants anion-PVP 363 
increased as the volume of the anionic compound increased (possibly due to 364 
coulombic repulsions between the anions bound to the polymer coil). In the same 365 
studies, they reported that basic compounds did not interact with PVP. However, other 366 
studies have shown interactions between some basic compounds and PVP, especially 367 
with compounds containing heterocyclic nitrogen atoms in highly conjugated rings 368 
(Karavas et al., 2007) or sulphonamide groups (Tajber et al., 2005). In these cases a 369 
hydrogen bond can form between the -N-H moiety of the drug and the oxygen of the 370 
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pyrrole group of PVP. That might be the case of olanzapine and pindolol, which contain 371 
heterocyclic nitrogen atoms in highly conjugated structures. 372 
4. Conclusions 373 
The used methodology provides an excellent way to study the supersaturation state of 374 
drug formulations, since the constant measurement of drug concentration in solution 375 
allows the determination of supersaturation extent and duration. The results from the 376 
present study demonstrate that the use of PVP polymers in the formulation of certain 377 
drugs can potentially improve their bioavailability by increasing the concentration of the 378 
drug in solution for a given period of time. In general, solubility of acidic compounds is 379 
clearly affected by PVP, although two different behaviors have been observed with 380 
such kind of compounds: in the first case PVP maintain a supersaturated system for a 381 
long period of time by the stabilization of the amorphous form of the compounds, as 382 
evidenced by the solid state characterization; in the second case PVP maintain the 383 
solution supersaturated in a higher degree compared to the compound alone, but only 384 
for a limited period of time. Then a crystalline form of the drug precipitates, and 385 
solubility drops to the equilibrium solubility value of the drug. 386 
The type of PVP and the PVP:drug ratio play a role in the supersaturation of the drugs, 387 
but there is not a clear relation between the obtained effect and the type and ratio of 388 
PVP, since different effects have been observed in different drugs. 389 
From the ten basic compounds studied in the present work, only two showed modified 390 
solubility behavior by the addition of PVP. This fact points out that the effect of PVP on 391 
solubility of basic drugs is not so evident, being the modification of solubility behavior 392 
by PVP highly drug-structure dependent. 393 
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Figure captions 488 
Figure 1: Supersaturation profile and parameters for bendroflumethiazide.  489 
Figure 2: (A) Supersaturation profile of bendroflumethiazide alone ( ) and in presence 490 
of different ratios of PVP K-12: 10% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), 60% 491 
( ), 70% ( ). (B) Variation of bendroflumethiazide solubility with the percentage of 492 
PVP K-12 present in the physical mixtures. 493 
Figure 3: Supersaturation profile of bendroflumethiazide alone ( ) and in presence of 494 
50% of PVP K-12 ( ), K-17 ( ), K-25 ( ), K-29/32 ( ), K-90 ( ), and S-630 ( ). 495 
Figure 4: Supersaturation profile of (A) diclofenac alone ( ) and in presence of 50% 496 
PVP K-25 ( ), and 50% of PVP K-29/32 ( ); (B) ketoprofen alone ( ),and in presence 497 
of 50% PVP K-12 ( ), K-17 ( ), K-25 ( ), K-29/32 ( ), and K-90 ( ); (C) warfarin 498 
alone ( ), and in presence of 5% PVP K-29/32 ( ), 10% PVP K-29/32 ( ), 15% PVP 499 
K-29/32 ( ), and 5% PVP S-630 ( ). 500 
Figure 5: Supersaturation profile of (A) benzthiazide alone ( ), and in presence of 501 
10% ( ), 50% ( ), and 75% ( ) of PVP S-630; (B) pindolol alone ( ), and in 502 
presence of 50% PVP K-90 ( ), 50% PVP S-630 ( ), and 70% PVP S-630 ( ); (C) 503 
olanzapine alone ( ), and in presence of 50% PVP K-25 ( ), 50% PVP K-90 ( ), and 504 
50% PVP S-630 ( ); (D) isoxicam alone ( ), and in presence of 50% of PVP K-12 (505 
), K-17 ( ), K-25 ( ), K-29/32 ( ), and K-90 ( ). 506 
Figure 6: Supersaturation profile of tetracaine alone ( ) and in presence of 50% of 507 
PVP K-12 ( ), K-17 ( ), K-25 ( ), K-29/32 ( ), K-90 ( ), and S-630 ( ). 508 
Figure 7: XRD spectra of (A) bendroflumethiazide: (a) commercial drug, (b) drug 509 
obtained after cheqsol experiments, (c) PVP K-12, (d) solid obtained after Cheqsol 510 
experiments of a mixture bendroflumethiazide:K-12 PVP at 50% ratio; (B) benzthiazide: 511 
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(a) commercial drug, (b) drug obtained after cheqsol experiments, (c) PVP S-630, (d) 512 
solid obtained after cheqsol experiments of a mixture bendroflumethiazide:S-630 PVP 513 
at 50% ratio. 514 
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Table 1: Physicochemical parameters of the compounds under study. pKa values provided are at 0.15M ionic strength and 25 ºC.9 
Compound Molecular structure Type pKa S0 (M) log So C max (M) 
Supersaturation 
ratio (Rs) 
Time of 
supersaturation 
(ts, min) 
Bendroflumethiazide 
N
H
NH
SS
NH2
OO
F
F
F
OO
 
H2A 
8.46 ± 0.02 
9.99 ± 0.01 
82 ± 3 -4.09 ± 0.02 1247 ± 405 13 ± 5 12 ± 3 
Benzthiazide 
Cl
SS
S
O O
O
O
NH
N
NH2
 
H2A 
6.64 ± 0.03 
9.22 ± 0.04 
12 ± 1 -4.89 ± 0.09 91 ± 11 7 ± 2 4 ± 1 
Diclofenac 
NH
OH O
Cl
Cl  
HA 4.13 ± 0.01 8 ± 2 -5.13 ± 0.10 198 ± 14 27 ± 4 5.1 ± 0.9 
Isoxicam 
S
O O
OH O
O
N
NH N
CH3
CH3
 
HA 3.84 ± 0.02 2.5 ± 0.8 -5.61 ± 0.14 137 ± 18 55 ± 7  6 ± 2 
Ketoprofen 
OH
O
CH3O  
HA 4.00 ± 0.01 585 ± 84 -3.24 ± 0.06 1550 ± 237 2.6 ± 0.2 19 ± 1 
Table(s)
Warfarin 
O
OH
CH3
O
O
 
HA 4.89 ± 0.01 20 ± 2 -4.70 ± 0.05 395 ± 63 20 ± 3 15 ± 4 
Dibucaine 
O
O
N
NH
N
CH3
CH3
CH3 
BH2
2+ 
2.02 ± 0.01 
8.64 ± 0.3 
96 ± 4 -4.02 ± 0.02 250 ± 17 2.6 ± 0.1 20 ± 13 
Olanzapine 
CH3
N
N
N
N
HSCH3
 
BH2
2+ 
5.59 ± 0.06 
8.03 ± 0.01 
59 ± 7 -4.23 ± 0.05 1884 ± 30 31.6 ± 0.5 5.6 ± 0.2 
Tetracaine 
O
O
NH
N
CH3
CH3
CH3
 
BH2
2+ 
2.33 ± 0.01 
8.53 ± 0.07 
819 ± 27 -3.09 ± 0.01 1236 ± 69 1.53 ± 0.07 19.8 ± 0.8 
Bupivacaine 
O
N
NH
CH3
CH3
CH3  
BH+ 8.18 ± 0.09 1172 ± 143 -2.93 ± 0.05 1582 ± 315 1.4 ± 0.1 7 ± 2 
Cyproheptadine 
CH3N
 
BH+ 9.40 ± 0.18 10.0 ± 0.9 -5.00 ± 0.04 160 ± 82 16 ± 6 12 ± 3 
Haloperidol 
Cl
F
OH
O
N
 
BH+ 8.44 ± 0.17 6.81 ± 0.94 -5.22 ± 0.13 303 ± 75 45 ± 9 5 ± 2 
Maprotiline 
CH3NH
 
BH+ 10.48 ± 0.1 15.8 ± 0.9 -4.80 ± 0.02 83 ± 13 5.0 ± 0.9 7 ± 2 
Papaverine 
O
CH3
O
CH3 N
O
CH3
CH3
O  
BH+ 6.44 ± 0.02 39 ± 11 -4.42 ± 0.13 2284 ± 515 59 ± 11 16 ± 5 
Pindolol 
O
OH
N
H
NH CH3
CH3
 
BH+ 9.48 ± 0.05 256 ± 45 -3.60 ± 0.08 4163 ± 612 15 ± 1 7.5 ± 1.5 
 Propranolol 
O OH
NH
CH3
CH3
 
BH+ 9.48 ± 0.02 329 ± 15 -3.48 ± 0.02 1976 ± 95 6.0 ± 0.1 17 ± 7 
